Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand–Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib

Grothey, 2013, Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, Lancet, 381, 303, 10.1016/S0140-6736(12)61900-X Li, 2015, Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 16, 619, 10.1016/S1470-2045(15)70156-7 Tabernero, 2015, Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial, Lancet Oncol, 16, 937, 10.1016/S1470-2045(15)00138-2 Yoshino, 2015, Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations, Invest New Drugs, 33, 740, 10.1007/s10637-014-0154-x Suenaga, 2016, Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer, Oncotarget, 7, 34811, 10.18632/oncotarget.9187 Wang, 2015, CCL5/CCR5 axis induces vascular endothelial growth factor mediated tumor angiogenesis in human osteosarcoma microenvironment, Carcinogenesis, 36, 104, 10.1093/carcin/bgu218 Song, 2000, Transcriptional regulation of RANTES expression in T lymphocytes, Immunol Rev, 177, 236, 10.1034/j.1600-065X.2000.17610.x Song, 2002, Functional domains and DNA-binding sequences of RFLAT-1/KLF13, a Krüppel-like transcription factor of activated T lymphocytes, J Biol Chem, 277, 30055, 10.1074/jbc.M204278200 Ishida, 2012, Pivotal role of the CCL5/CCR5 interaction for recruitment of endothelial progenitor cells in mouse wound healing, J Clin Invest, 122, 711, 10.1172/JCI43027 Balkwill, 2004, Cancer and the chemokine network, Nat Rev Cancer, 4, 540, 10.1038/nrc1388 Musha, 2005, Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma, Int J Cancer, 116, 949, 10.1002/ijc.21135 Liu, 2015, CCL5 promotes vascular endothelial growth factor expression and induces angiogenesis by down-regulating miR-199a in human chondrosarcoma cells, Cancer Lett, 357, 476, 10.1016/j.canlet.2014.11.015 An, 2002, Modulating influence on HIV/AIDS by interacting RANTES gene variants, Proc Natl Acad Sci U S A, 99, 10002, 10.1073/pnas.142313799 Mross, 2012, A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors, Clin Cancer Res, 18, 2658, 10.1158/1078-0432.CCR-11-1900 Wilhelm, 2011, Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity, Int J Cancer, 129, 245, 10.1002/ijc.25864 Carmeliet, 2011, Molecular mechanisms and clinical applications of angiogenesis, Nature, 473, 298, 10.1038/nature10144 Hudson, 2014, Differential apicobasal VEGF signaling at vascular blood–neural barriers, Dev Cell, 30, 541, 10.1016/j.devcel.2014.06.027 Takahashi, 2004, A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential signaling via VEGF receptor-1, J Biol Chem, 279, 46304, 10.1074/jbc.M403687200 Lacouture, 2008, Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib, Ann Oncol, 19, 1955, 10.1093/annonc/mdn389 Zhang, 2013, A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells, Cell Res, 23, 394, 10.1038/cr.2012.178